FOXM1 contributes to treatment failure in acute myeloid leukemia

about

FOXM1 contributes to treatment failure in acute myeloid leukemia

Item

http://www.wikidata.org/entity/Q58792314

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

FOXM1 contributes to treatment failure in acute myeloid leukemia

@en

FOXM1 contributes to treatment failure in acute myeloid leukemia

@nl

type

Item

label

FOXM1 contributes to treatment failure in acute myeloid leukemia

@en

FOXM1 contributes to treatment failure in acute myeloid leukemia

@nl

prefLabel

FOXM1 contributes to treatment failure in acute myeloid leukemia

@en

FOXM1 contributes to treatment failure in acute myeloid leukemia

@nl

P1476

FOXM1 contributes to treatment failure in acute myeloid leukemia

@en

P2093

Anand Patel

http://www.w3.org/2001/XMLSchema#string

Andrei L Gartel

http://www.w3.org/2001/XMLSchema#string

Irum Khan

http://www.w3.org/2001/XMLSchema#string

John D Crispino

http://www.w3.org/2001/XMLSchema#string

Li Liu

http://www.w3.org/2001/XMLSchema#string

Marianna Halasi

http://www.w3.org/2001/XMLSchema#string

Nadim Mahmud

http://www.w3.org/2001/XMLSchema#string

Nandini Kalakota

http://www.w3.org/2001/XMLSchema#string

Nathan Aardsma

http://www.w3.org/2001/XMLSchema#string

Olga Frankfurt

http://www.w3.org/2001/XMLSchema#string

P2860

FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.

Genomic Classification and Prognosis in Acute Myeloid Leukemia.

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

FoxM1 is required for execution of the mitotic programme and chromosome stability

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

P31

scholarly article

P356

10.1172/JCI.INSIGHT.121583

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30089730

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

6129129

http://www.w3.org/2001/XMLSchema#string